ID

14769

Description

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe); ODM derived from: https://clinicaltrials.gov/show/NCT02269813

Lien

https://clinicaltrials.gov/show/NCT02269813

Mots-clés

Versions (1)
  1. 27/04/2016 27/04/2016 -
Téléchargé le

27 avril 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT02269813

Anglais

Eligibility Breast Cancer NCT02269813

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
women with histologically proven invasive stage 1 and 2 breast cancer
Description

Gender | Invasive breast carcinoma

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0853879
hormone receptor positive according to local standards
Description

Hormone Receptor Positive

Type de données

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C1446409
her2 negative - i.e. ihc 0-1+, or fish or other ish non-amplified (locally assessed)
Description

Human epidermal growth factor 2 negative carcinoma of breast | Immunohistochemistry | Fluorescent in Situ Hybridization

Type de données

boolean

Alias
UMLS CUI [1]
C2316304
UMLS CUI [2]
C0021044
UMLS CUI [3]
C0162789
axillary lymph node status: 0-3 involved (macro metastases i.e. >2mm or micro metastases i.e. >0.2-2mm)
Description

axillary lymph node Status | Macrometastasis | Neoplasm Micrometastasis

Type de données

boolean

Alias
UMLS CUI [1,1]
C1279048
UMLS CUI [1,2]
C0449438
UMLS CUI [2]
C3829229
UMLS CUI [3]
C1513276
≥ 18 years of age at time of consent
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
patients must be eligible to receive adjuvant chemotherapy and endocrine therapy as defined by a good karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity
Description

eligible Adjuvant Chemotherapy Hormone Therapy | Karnofsky Performance Status | Medical contraindication Hematological Disease Heart Diseases Liver diseases | Comorbidity

Type de données

boolean

Alias
UMLS CUI [1,1]
C1548635
UMLS CUI [1,2]
C0085533
UMLS CUI [1,3]
C0279025
UMLS CUI [2]
C0206065
UMLS CUI [3,1]
C1301624
UMLS CUI [3,2]
C0018939
UMLS CUI [3,3]
C0018799
UMLS CUI [3,4]
C0023895
UMLS CUI [4]
C0009488
written informed consent
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
≥4 involved axillary nodes
Description

Axillary lymph node group

Type de données

boolean

Alias
UMLS CUI [1]
C0729594
multi-centric disease with more than 2 clinically relevant lesions
Description

Multicentric Breast Carcinoma Lesion

Type de données

boolean

Alias
UMLS CUI [1,1]
C2986664
UMLS CUI [1,2]
C0221198
hr negative or her2 positive/amplified (locally assessed)
Description

Hormone Receptor Negative | HER2-positive carcinoma of breast

Type de données

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C0205160
UMLS CUI [2]
C1960398
previous diagnosis of malignancy unless disease free for 10 years
Description

Prior diagnosis Malignant Neoplasms

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332132
UMLS CUI [1,2]
C0006826
metastatic disease
Description

Neoplasm Metastasis

Type de données

boolean

Alias
UMLS CUI [1]
C0027627
tumor sample shipped to agendia with ≤ 30% tumor cells or that fails qa or qc criteria
Description

Tumor tissue sample | quality assurance | quality control

Type de données

boolean

Alias
UMLS CUI [1]
C0475358
UMLS CUI [2]
C0178932
UMLS CUI [3]
C0034378
women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer
Description

Gender | Adjuvant Chemotherapy Breast Carcinoma | Neoadjuvant Therapy Breast Carcinoma

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2,1]
C0085533
UMLS CUI [2,2]
C0678222
UMLS CUI [3,1]
C0600558
UMLS CUI [3,2]
C0678222
Retour au début de la page

Similar models

Eligibility Breast Cancer NCT02269813

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Invasive breast carcinoma
Item
women with histologically proven invasive stage 1 and 2 breast cancer
boolean
C0079399 (UMLS CUI [1])
C0853879 (UMLS CUI [2])
Hormone Receptor Positive
Item
hormone receptor positive according to local standards
boolean
C0019929 (UMLS CUI [1,1])
C1446409 (UMLS CUI [1,2])
Human epidermal growth factor 2 negative carcinoma of breast | Immunohistochemistry | Fluorescent in Situ Hybridization
Item
her2 negative - i.e. ihc 0-1+, or fish or other ish non-amplified (locally assessed)
boolean
C2316304 (UMLS CUI [1])
C0021044 (UMLS CUI [2])
C0162789 (UMLS CUI [3])
axillary lymph node Status | Macrometastasis | Neoplasm Micrometastasis
Item
axillary lymph node status: 0-3 involved (macro metastases i.e. >2mm or micro metastases i.e. >0.2-2mm)
boolean
C1279048 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C3829229 (UMLS CUI [2])
C1513276 (UMLS CUI [3])
Age
Item
≥ 18 years of age at time of consent
boolean
C0001779 (UMLS CUI [1])
eligible Adjuvant Chemotherapy Hormone Therapy | Karnofsky Performance Status | Medical contraindication Hematological Disease Heart Diseases Liver diseases | Comorbidity
Item
patients must be eligible to receive adjuvant chemotherapy and endocrine therapy as defined by a good karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity
boolean
C1548635 (UMLS CUI [1,1])
C0085533 (UMLS CUI [1,2])
C0279025 (UMLS CUI [1,3])
C0206065 (UMLS CUI [2])
C1301624 (UMLS CUI [3,1])
C0018939 (UMLS CUI [3,2])
C0018799 (UMLS CUI [3,3])
C0023895 (UMLS CUI [3,4])
C0009488 (UMLS CUI [4])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Axillary lymph node group
Item
≥4 involved axillary nodes
boolean
C0729594 (UMLS CUI [1])
Multicentric Breast Carcinoma Lesion
Item
multi-centric disease with more than 2 clinically relevant lesions
boolean
C2986664 (UMLS CUI [1,1])
C0221198 (UMLS CUI [1,2])
Hormone Receptor Negative | HER2-positive carcinoma of breast
Item
hr negative or her2 positive/amplified (locally assessed)
boolean
C0019929 (UMLS CUI [1,1])
C0205160 (UMLS CUI [1,2])
C1960398 (UMLS CUI [2])
Prior diagnosis Malignant Neoplasms
Item
previous diagnosis of malignancy unless disease free for 10 years
boolean
C0332132 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
Neoplasm Metastasis
Item
metastatic disease
boolean
C0027627 (UMLS CUI [1])
Tumor tissue sample | quality assurance | quality control
Item
tumor sample shipped to agendia with ≤ 30% tumor cells or that fails qa or qc criteria
boolean
C0475358 (UMLS CUI [1])
C0178932 (UMLS CUI [2])
C0034378 (UMLS CUI [3])
Gender | Adjuvant Chemotherapy Breast Carcinoma | Neoadjuvant Therapy Breast Carcinoma
Item
women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer
boolean
C0079399 (UMLS CUI [1])
C0085533 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
C0600558 (UMLS CUI [3,1])
C0678222 (UMLS CUI [3,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial